BFC Planning’s Acadia Pharmaceuticals ACAD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$181 Buy
+9
New +$242 ﹤0.01% 3360
2026
Q1
– Sell
-38
Closed -$1.02K – 3036
2025
Q4
$1.02K Buy
+38
New +$908 ﹤0.01% 2789

Other funds holding ACAD

BFC Planning's ACAD Position: Q3 2026 in Review

BFC Planning opened a new position in Acadia Pharmaceuticals (ACAD) in Q3 2026: 9 shares worth $181. The stake represents ﹤0.01% of the portfolio and ranks #3360 among its holdings. This is a return to the name: BFC Planning previously reported a position in ACAD as recently as Q4 2025.

BFC Planning first reported a position in ACAD in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.02K in Q4 2025. 263 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.

  • BFC Planning held 9 shares of Acadia Pharmaceuticals worth $181 as of Q3 2026.
  • Acadia Pharmaceuticals was a new BFC Planning position in Q3 2026.
  • Acadia Pharmaceuticals made up ﹤0.01% of BFC Planning's portfolio in Q3 2026, its #3360 holding.
  • BFC Planning first reported a position in Acadia Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
  • BFC Planning's Acadia Pharmaceuticals position peaked at $1.02K in Q4 2025.
  • 263 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.

Based on BFC Planning's 13F filing for Q3 2026, filed 13 Nov 2026.